News

Landos Biopharma Raises $60 Million in Series B Financing

Read More

Landos Biopharma Announces Publication of Results from First-in-Human Phase 1 Study of BT-11 in Healthy Volunteers

Read More

Landos Biopharma Announces Publication of Results from Non-clinical Toxicity Studies Further Characterizing the Safety Profile of BT-11

Read More

Landos Biopharma Announces Publication Supporting Novel, Dual Mechanism of Action for BT-11 in Models of IBD

Read More

Dr. Bassaganya-Riera, Landos Chairman & CEO, Provides Corporate and Clinical Update

Read More

Landos Biopharma Announces Final Safety Results from Phase I Study of BT-11 in Healthy Volunteers

Read More